Share
14 Posts.
lightbulb Created with Sketch. 29
clock Created with Sketch.
23/04/20
11:36
Share
Originally posted by Galilee13:
↑
Nice work stockfella Appointing 2 brokers and 1 with an Asian base sets this company up very well, particularly if they still want to IPO the Chinese business on the HKSE. Timing of Q3 look very ambitious to me. Although things seem to be moving pretty quickly ATM. if they list late Q3 then they may sneak in the Q2 financials. If this is the plan I really hope they bank some serious revenue over the next 2 months. The only other potential deal we know about is with FCL. They will definitely need FDA for the patch and NMPA for the prizma to get the IPO anyway without any increase in revenue. Hence US and Chinese brokers.... NMPA for the patch and G3 and G4 of the prizma will entice new investors, amongst other things. But Q3 for CR doesn't help with this Magna CN due next week. I can't see the company doing a CR on ASX for a min of $5m with a Nasdaq raising coming. Maybe they extend the Magna CN for 6mths to coincide. Maybe Yacov just pays it out? Will find out soon enough. These last few announcements are definitely great, but not price sensitive. They are intentions only. Nothing firm it terms of revenue or raising amounts nor timings. And yes, if they list on the Nasdaq it WILL dilute the ASX share price. More shares on issue, just tradable across 2 exchanges.
Expand
Hi G13 - To $tockfella's point - what if we go down the HKEx listing route and IPO G Medical USA rather than the parent company proceeding with a dual listing to avoid or minimise dilution? Obviously the details from today's announcement are a little thin but food for thought...